> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Immuneering Taps Grant C. Bogle For Its Board As It Prepares For Commercialization
- URL: https://www.bullished.co/immuneering-taps-grant-c-bogle-for-its-board-as-it-prepares-for-commercialization-529a8b2a/
- Published: 2026-11-09T21:57:27.000Z
- Updated: 2026-11-09T21:57:27.000Z
- Description: The former TESARO commercial chief oversaw ZEJULA's U.S. launch; Immuneering's lead cancer drug is still in clinical development.
- Author: Matteo Parrino
- Tags: SEC Filings, IMRX, Industry: Healthcare

[Immuneering](https://www.bullished.co/tag/imrx/), which develops cancer medicines, [appointed Grant C. Bogle](https://www.sec.gov/Archives/edgar/data/0001790340/000179034026000099/imrx-20261109.htm?ref=bullished.co) to its board Monday while preparing commercially for atebimetinib, its lead drug candidate still in clinical development. The appointment, detailed in an SEC filing, brings the company a director who oversaw the U.S. launch of the ovarian-cancer drug ZEJULA.

## Atebimetinib Before A Potential Launch

Immuneering co-founder and CEO Ben Zeskind said in the company's appointment announcement that Bogle would help guide its [commercial readiness work](https://www.globenewswire.com/news-release/2026/11/09/3398289/0/en/immuneering-appoints-accomplished-commercial-leader-grant-bogle-to-board-of-directors.html?ref=bullished.co) as atebimetinib moves through clinical development. Immuneering has no medicines approved for sale.

The company's pancreatic-cancer results presented at ASCO in June put [median overall survival](https://www.globenewswire.com/news-release/2026/11/09/3398289/0/en/immuneering-appoints-accomplished-commercial-leader-grant-bogle-to-board-of-directors.html?ref=bullished.co) at 17.3 months for atebimetinib combined with mGnP in first-line treatment.

Atebimetinib is a daily pill targeting MEK, a protein. In its annual report for the fiscal year ended December 31, 2025, Immuneering described plans to start a global late-stage trial in first-line pancreatic cancer, with enrollment expected to reach about 510 patients.

The drug belongs to a category Immuneering calls Deep Cyclic Inhibitors: small-molecule oral medicines designed to interrupt cancer-driving signals cyclically, rather than maintain continuous disruption. The company uses its own bioinformatics tools and three-dimensional tumor models to design drugs.

## From ZEJULA To Oncology Restructuring

Bogle's pharmaceutical and biotechnology career spans more than four decades, covering oncology marketing, sales, strategy and market access. As TESARO's chief commercial officer, he established its U.S. commercial business and oversaw ZEJULA's launch.

He also ran Epizyme as president and CEO, leading a restructuring that cut costs and accelerated revenue growth before Ipsen bought the company in 2022\. While on Nuvalent's board, Bogle worked with management on launch planning; GlaxoSmithKline bought Nuvalent in 2026.

Immuneering appointed Bogle as a Class III director. He will be paid under its arrangements for non-employee directors.

Immuneering's other clinical candidate, envometinib, is paused internally while the company seeks partners. Earlier discovery programs target additional cancer pathways.

Learn

- [Item 5.02: directors and officers leave or join, or executive pay is set →](https://www.bullished.co/learn/8-k-items-explained/#item-502-directors-and-officers-leave-or-join-or-executive-pay-is-set)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Immuneering Corp (IMRX)](https://www.sec.gov/Archives/edgar/data/0001790340/000179034026000099/imrx-20261109.htm?ref=bullished.co) — SEC EDGAR
- [Immuneering Appoints Accomplished Commercial Leader Grant](https://www.globenewswire.com/news-release/2026/11/09/3398289/0/en/immuneering-appoints-accomplished-commercial-leader-grant-bogle-to-board-of-directors.html?ref=bullished.co) — globenewswire.com

### More on Immuneering

- [Immuneering Pulls Cash Runway In To Late 2028 As It Enlarges Pancreatic Cancer Trial](https://www.bullished.co/immuneering-pulls-cash-runway-in-to-late-2028-as-it-enlarges-pancreatic-cancer-trial-48a65e9f/)
- [Immuneering Lifts Phase 3 Pancreatic Cancer Trial To 570 Patients As Phase 2 Patients Outlive Projections](https://www.bullished.co/immuneering-lifts-phase-3-pancreatic-cancer-trial-to-570-patients-as-phase-2-patients-2d5f2f89/)

[All Immuneering (IMRX) coverage →](https://www.bullished.co/tag/imrx/)